- Home
- SOL vs PBYI Comparison
SOL vs PBYI Comparison
Compare SOL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- PBYI
- Stock Information
- Founded
- SOL 2005
- PBYI 2010
- Country
- SOL United States
- PBYI United States
- Employees
- SOL N/A
- PBYI N/A
- Industry
- SOL Semiconductors
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- PBYI Health Care
- Exchange
- SOL Nasdaq
- PBYI Nasdaq
- Market Cap
- SOL 98.5M
- PBYI 237.2M
- IPO Year
- SOL 2008
- PBYI N/A
- Fundamental
- Price
- SOL $1.84
- PBYI $5.19
- Analyst Decision
- SOL Strong Buy
- PBYI Strong Buy
- Analyst Count
- SOL 2
- PBYI 1
- Target Price
- SOL $4.50
- PBYI $7.00
- AVG Volume (30 Days)
- SOL 208.5K
- PBYI 489.2K
- Earning Date
- SOL 11-13-2025
- PBYI 11-06-2025
- Dividend Yield
- SOL N/A
- PBYI N/A
- EPS Growth
- SOL N/A
- PBYI 434.29
- EPS
- SOL N/A
- PBYI 0.97
- Revenue
- SOL $68,445,000.00
- PBYI $238,062,000.00
- Revenue This Year
- SOL N/A
- PBYI N/A
- Revenue Next Year
- SOL $45.37
- PBYI N/A
- P/E Ratio
- SOL N/A
- PBYI $5.32
- Revenue Growth
- SOL N/A
- PBYI 8.63
- 52 Week Low
- SOL $1.04
- PBYI $2.32
- 52 Week High
- SOL $2.68
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- SOL 44.80
- PBYI 54.99
- Support Level
- SOL $1.81
- PBYI $5.06
- Resistance Level
- SOL $1.87
- PBYI $5.59
- Average True Range (ATR)
- SOL 0.04
- PBYI 0.26
- MACD
- SOL -0.00
- PBYI -0.00
- Stochastic Oscillator
- SOL 27.30
- PBYI 45.80
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.